Clinical Trials Logo

Chronic Graft vs Host Disease clinical trials

View clinical trials related to Chronic Graft vs Host Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03683498 Completed - Clinical trials for Chronic Graft vs Host Disease

Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease

GVHD-TReG
Start date: September 25, 2018
Phase: Phase 1
Study type: Interventional

A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib

NCT ID: NCT01221766 Completed - Clinical trials for Graft vs Host Disease

Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease

Start date: September 2010
Phase: N/A
Study type: Observational

This research study will help us learn more about how chronic graft-versus-host disease affects the skin, hair and nails. We are interested in knowing if hair and nail problems predict worse disease. This information may help us treat patients like you in the future.

NCT ID: NCT00495755 Completed - Clinical trials for Chronic Graft-vs.-Host Disease

Campath in Chronic GVHD

Start date: July 2007
Phase: Phase 1
Study type: Interventional

The CD52 antigen, which is targeted by alemtuzumab, is highly expressed on mature T lymphocytes, monocytes and monocyte-derived dendritic cells as well as on mature B cells. Due to its more promiscuous effect on immune cells, alemtuzumab not only targets antibody producing B lymphocytes as does rituximab, but also targets alloreactive T lymphocytes and dendritic cells that also contribute to the complex pathogenesis of chronic GVHD. Our hypothesis is that alemtuzumab will be effective in the treatment of chronic GVHD through its promiscuous depletion of alloreactive T lymphocytes, dendritic cells as well as antibody producing mature B-lymphocytes.